Characterization of the outer domain of the gp120 glycoprotein from human immunodeficiency virus type 1
about
Structural definition of a conserved neutralization epitope on HIV-1 gp120Advances in structure-based vaccine designHIV-1 neutralizing antibodies: understanding nature's pathwaysStructural plasticity and conformational transitions of HIV envelope glycoprotein gp120Outer Domain of HIV-1 gp120: Antigenic Optimization, Structural Malleability, and Crystal Structure with Antibody VRC-PG04Induction of a Tier-1-like Phenotype in Diverse Tier-2 Isolates by Agents that Guide HIV-1 Env to Perturbation-sensitive, Non-native States.Soluble CD4 and CD4-mimetic compounds inhibit HIV-1 infection by induction of a short-lived activated state.Constrained use of CCR5 on CD4+ lymphocytes by R5X4 HIV-1: efficiency of Env-CCR5 interactions and low CCR5 expression determine a range of restricted CCR5-mediated entry.Mapping the immune response to the outer domain of a human immunodeficiency virus-1 clade C gp120Rational antibody-based HIV-1 vaccine design: current approaches and future directionsContribution of intrinsic reactivity of the HIV-1 envelope glycoproteins to CD4-independent infection and global inhibitor sensitivity.Asn 362 in gp120 contributes to enhanced fusogenicity by CCR5-restricted HIV-1 envelope glycoprotein variants from patients with AIDS.Eliciting neutralizing antibodies with gp120 outer domain constructs based on M-group consensus sequence.Conformational characterization of aberrant disulfide-linked HIV-1 gp120 dimers secreted from overexpressing cells.Design of a non-glycosylated outer domain-derived HIV-1 gp120 immunogen that binds to CD4 and induces neutralizing antibodies.Elicitation of HIV-1-neutralizing antibodies against the CD4-binding site.Rapid conformational epitope mapping of anti-gp120 antibodies with a designed mutant panel displayed on yeastGenetic and functional analysis of R5X4 human immunodeficiency virus type 1 envelope glycoproteins derived from two individuals homozygous for the CCR5delta32 alleleConformational and structural features of HIV-1 gp120 underlying the dual receptor antagonism by cross-reactive neutralizing antibody m18Structure-based vaccine design in HIV: blind men and the elephant?Conformational alterations in the CD4 binding cavity of HIV-1 gp120 influencing gp120-CD4 interactions and fusogenicity of HIV-1 envelopes derived from brain and other tissuesMammalian production of an isotopically enriched outer domain of the HIV-1 gp120 glycoprotein for NMR spectroscopy.Rational design of vaccines to elicit broadly neutralizing antibodies to HIV-1.High-mannose glycan-dependent epitopes are frequently targeted in broad neutralizing antibody responses during human immunodeficiency virus type 1 infection.Antigenicity and Immunogenicity in HIV-1 Antibody-Based Vaccine DesignDesign of an Escherichia coli expressed HIV-1 gp120 fragment immunogen that binds to b12 and induces broad and potent neutralizing antibodies.Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C.Immune focusing and enhanced neutralization induced by HIV-1 gp140 chemical cross-linking.Tissue-specific sequence alterations in the human immunodeficiency virus type 1 envelope favoring CCR5 usage contribute to persistence of dual-tropic virus in the brain.Enhanced exposure of the CD4-binding site to neutralizing antibodies by structural design of a membrane-anchored human immunodeficiency virus type 1 gp120 domainImmunogenicity of recombinant human immunodeficiency virus type 1-like particles expressing gp41 derivatives in a pre-fusion stateThe selection of low envelope glycoprotein reactivity to soluble CD4 and cold during simian-human immunodeficiency virus infection of rhesus macaques.Accessing the human repertoire for broadly neutralizing HIV antibodies.Surface plasmon resonance for vaccine design and efficacy studies: recent applications and future trends.Alterations in the immunogenic properties of soluble trimeric human immunodeficiency virus type 1 envelope proteins induced by deletion or heterologous substitutions of the V1 loop.HIV-1 envelope glycoprotein immunogens to induce broadly neutralizing antibodies.Tryptophan 375 stabilizes the outer-domain core of gp120 for HIV vaccine immunogen design.Paring Down HIV Env: Design and Crystal Structure of a Stabilized Inner Domain of HIV-1 gp120 Displaying a Major ADCC Target of the A32 Region.Immunogenicity of the outer domain of a HIV-1 clade C gp120.Epitopes for broad and potent neutralizing antibody responses during chronic infection with human immunodeficiency virus type 1.
P2860
Q24655948-574D7DCB-B333-4B0C-AEAC-FA4B4AC24DE0Q26824545-D743168C-E189-45CF-8593-EA172F3D58FCQ27000480-A37C1AD8-BEBA-4111-A858-7439E6AB9BD8Q27327645-CBFB3911-6DD6-4073-A25E-995747A2E6BCQ27675468-1BDB6B73-EE39-4850-882D-631BBCDDF3DAQ30401836-ACD32369-D42D-43EB-8EBB-AA4DD38CEC0DQ33426352-9FCFA1B3-4ADB-4BED-B087-ACB9F76CD399Q33857491-23691574-D53C-4F34-925F-4533DAE52363Q33910507-957A92BB-43BA-41C5-ABA8-631AD41C2577Q33937285-38EB7654-6405-484C-8330-3C909B4959D1Q33951963-7513C771-BBE8-4E3F-B09E-08839EAFEC56Q34008699-C2836A51-C28F-411E-828F-28E46F8E08FAQ34016706-1E6058E6-E820-4480-8FB0-E33C7AB41BE9Q34020606-96B486C4-7E24-4CA1-8930-17C0304BC8FEQ34094476-A25ED608-6EDF-47ED-A2C6-9A2E6E9272E9Q34133551-820EC6B0-E368-4CA7-9356-0FFF78998B87Q34480254-33D5C696-D19D-43B1-81EB-44EFFAB8054EQ34545588-46B284CB-96B2-4F64-B321-0B745A3FB5CDQ34934438-2798B1E3-549A-4106-A663-9D819D517542Q34987048-62C85FD8-1505-4E08-8149-D35416924DDDQ35069459-AF2E3F14-F972-41C0-9CA4-2230DE0AAB47Q35097577-38660E0B-6B09-4857-8510-5144DC4A0BEFQ35603504-4D5F4422-FB7F-417F-A712-72BD3A4A9E48Q35826509-96BF0F2E-F696-4031-9B43-FF4EA5236ADFQ36447540-BC7D5AFA-AE0B-4DE7-9945-1E5BC7043A37Q36742228-A24515A9-4EA8-485A-AB7F-7B6C58032AB9Q36974754-6A7DBB62-3A2C-4B7A-BECD-AF27D104587AQ37123168-55098AFC-6238-467A-809F-07A4B8665C7AQ37191794-B63B6AC9-3042-4BBB-BCEB-8E2761DFEF52Q37192171-4B04870B-AD83-40F3-A8FD-335983E02DF8Q37250899-4C4F7203-7412-4092-88AC-763DA75A9EDCQ37547702-C1FF8F34-7499-4242-83CB-4934C56B0655Q37694976-B6FE90CE-F9F6-4DAF-89BD-DBFA70D92FD7Q37762275-D2D727FA-0BBA-45D7-903D-1F1EF440F844Q38342167-6B05ED76-B3D5-4155-957F-3523DB5C54A8Q38665463-50129ECC-0BBF-4EAE-87D7-983D69ABA07DQ38810452-45F0D464-EC4E-461E-BDBB-A0AD7871C3C8Q40730039-280365ED-E550-415A-927B-9EF4DD4583D4Q41961460-4C6A3083-6911-40B5-97E3-56DE96AE86B4Q42959357-237CCE2D-7A95-4456-A6BD-A0B44A646861
P2860
Characterization of the outer domain of the gp120 glycoprotein from human immunodeficiency virus type 1
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on December 2004
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Characterization of the outer ...... immunodeficiency virus type 1
@en
Characterization of the outer ...... immunodeficiency virus type 1.
@nl
type
label
Characterization of the outer ...... immunodeficiency virus type 1
@en
Characterization of the outer ...... immunodeficiency virus type 1.
@nl
prefLabel
Characterization of the outer ...... immunodeficiency virus type 1
@en
Characterization of the outer ...... immunodeficiency virus type 1.
@nl
P2093
P2860
P1433
P1476
Characterization of the outer ...... immunodeficiency virus type 1
@en
P2093
Liping Wang
Miroslaw K Gorny
Susan Zolla-Pazner
Svetla Kurteva
Vesko Tomov
Xinping Ren
Xinzhen Yang
P2860
P304
12975-12986
P356
10.1128/JVI.78.23.12975-12986.2004
P407
P577
2004-12-01T00:00:00Z